Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Clin Transplant ; 32(5): e13229, 2018 05.
Article in English | MEDLINE | ID: mdl-29498104

ABSTRACT

BACKGROUND: The preoperative workup of orthotopic liver transplantation (OLT) patients is practically complex given the need for multiple imaging modalities. We recently demonstrated in our proof-of-concept study the value of a one-stop-shop approach using cardiovascular MRI (CMR) to address this complex problem. However, this approach requires further validation in a larger cohort, as detection of hepatocellular carcinoma (HCC) as well as cardiovascular risk assessment is critically important in these patients. We hypothesized that coronary risk assessment and HCC detectability is acceptable using the one-stop-shop CMR approach. METHODS: In this observational study, patients underwent CMRI evaluation including cardiac function, stress CMR, thoracoabdominal MRA, and abdominal MRI on a standard MRI scanner in one examination. RESULTS: Over 8 years, 252 OLT candidates underwent evaluation in the cardiac MRI suit. The completion rates for each segment of the CMR examination were 99% for function, 95% completed stress CMR, 93% completed LGE for viability, 85% for liver MRI, and 87% for MRA. A negative CMR stress examination had 100% CAD event-free survival at 12 months. A total of 63 (29%) patients proceeded to OLT. Explant pathology confirmed detection/exclusion of HCC. CONCLUSIONS: This study further defines the population suitable for the one-stop-shop CMR concept for preop evaluation of OLT candidates providing a road map for integrated testing in this complex patient population for evaluation of cardiac risk and detection of HCC lesions.


Subject(s)
Carcinoma, Hepatocellular/pathology , Heart Diseases/pathology , Liver Failure/surgery , Liver Neoplasms/pathology , Liver Transplantation/adverse effects , Magnetic Resonance Imaging/methods , Risk Assessment/methods , Carcinoma, Hepatocellular/etiology , Cohort Studies , Female , Follow-Up Studies , Heart Diseases/etiology , Humans , Liver Neoplasms/etiology , Male , Middle Aged , Preoperative Care , Prognosis
2.
HPB (Oxford) ; 18(1): 88-97, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26776856

ABSTRACT

OBJECTIVES: We report single center experience on the outcome and toxicity of SBRT alone or in combination with surgery for inoperable primary and metastatic liver tumors between 2007 and 2014. PATIENTS AND METHODS: Patients with 1-4 hepatic lesions and tumor diameter ≤9 cm received SBRT at 46.8Gy ± 3.7 in 4-6 fractions. The primary end point was local control with at least 6 months of radiographic followup, and secondary end points were toxicity and survival. RESULTS: Eighty-seven assessable patients (114 lesions) completed liver SBRT for hepatoma (39) or isolated metastases (48) with a median followup of 20.3 months (range 1.9-64.1). Fourteen patients underwent liver transplant with SBRT as a bridging treatment or for tumor downsizing. Eight patients completed hepatic resections in combination with planned SBRT for unresectable tumors. Two-year local control was 96% for hepatoma and 93.8% for metastases; it was 100% for lesions ≤4 cm. Two-year overall survival was 82.3% (hepatoma) and 64.3% (metastases). No incidence of grade >2 treatment toxicity was observed. CONCLUSION: In this retrospective analysis we demonstrate that liver SBRT alone or in combination with surgery is safe and effective for the treatment of isolated inoperable hepatic malignancies and provides excellent local control rates.


Subject(s)
Carcinoma, Hepatocellular/radiotherapy , Carcinoma, Hepatocellular/surgery , Hepatectomy , Liver Neoplasms/radiotherapy , Liver Neoplasms/surgery , Liver Transplantation , Neoadjuvant Therapy , Radiosurgery , Adult , Aged , Aged, 80 and over , Carcinoma, Hepatocellular/mortality , Carcinoma, Hepatocellular/pathology , Dose Fractionation, Radiation , Female , Hepatectomy/adverse effects , Hepatectomy/mortality , Humans , Kaplan-Meier Estimate , Liver Neoplasms/mortality , Liver Neoplasms/pathology , Liver Neoplasms/secondary , Liver Transplantation/adverse effects , Liver Transplantation/mortality , Male , Middle Aged , Multimodal Imaging/methods , Neoadjuvant Therapy/adverse effects , Neoadjuvant Therapy/mortality , Pennsylvania , Radiosurgery/adverse effects , Radiosurgery/mortality , Radiotherapy Planning, Computer-Assisted , Radiotherapy, Adjuvant , Retrospective Studies , Risk Factors , Time Factors , Tomography, Emission-Computed, Single-Photon , Tomography, X-Ray Computed , Treatment Outcome , Tumor Burden
3.
Transplantation ; 96(9): 827-33, 2013 Nov 15.
Article in English | MEDLINE | ID: mdl-23982342

ABSTRACT

BACKGROUND: Preoperative cardiovascular risk stratification in orthotopic liver transplantation candidates has proven challenging due to limitations of current noninvasive modalities. Additionally, the preoperative workup is logistically cumbersome and expensive given the need for separate cardiac, vascular, and abdominal imaging. We evaluated the feasibility of a "one-stop shop" in a magnetic resonance suite, performing assessment of cardiac structure, function, and viability, along with simultaneous evaluation of thoracoabdominal vasculature and liver anatomy. METHODS: In this pilot study, patients underwent steady-state free precession sequences and stress cardiac magnetic resonance (CMR), thoracoabdominal magnetic resonance angiography, and abdominal magnetic resonance imaging (MRI) on a standard MRI scanner. Pharmacologic stress was performed using regadenoson, adenosine, or dobutamine. Viability was assessed using late gadolinium enhancement. RESULTS: Over 2 years, 51 of 77 liver transplant candidates (mean age, 56 years; 35% female; mean Model for End-stage Liver Disease score, 10.8; range, 6-40) underwent MRI. All referred patients completed standard dynamic CMR, 98% completed stress CMR, 82% completed late gadolinium enhancement for viability, 94% completed liver MRI, and 88% completed magnetic resonance angiography. The mean duration of the entire study was 72 min, and 45 patients were able to complete the entire examination. Among all 51 patients, 4 required follow-up coronary angiography (3 for evidence of ischemia on perfusion CMR and 1 for postoperative ischemia), and none had flow-limiting coronary disease. Nine proceeded to orthotopic liver transplantation (mean 74 days to transplantation after MRI). There were six ascertained mortalities in the nontransplant group and one death in the transplanted group. Explant pathology confirmed 100% detection/exclusion of hepatocellular carcinoma. No complications during CMR examination were encountered. CONCLUSIONS: In this proof-of-concept study, it appears feasible to perform a comprehensive, efficient, and safe preoperative liver transplant imaging in a CMR suite-a one-stop shop, even in seriously ill patients.


Subject(s)
Cardiovascular Diseases/diagnosis , Liver Diseases/diagnosis , Liver Diseases/surgery , Liver Transplantation , Magnetic Resonance Imaging , Adenosine , Adult , Cardiovascular Diseases/complications , Cardiovascular Diseases/mortality , Contrast Media , Coronary Angiography , Dobutamine , Feasibility Studies , Female , Humans , Liver Diseases/complications , Liver Diseases/mortality , Liver Transplantation/adverse effects , Magnetic Resonance Angiography , Male , Middle Aged , Pilot Projects , Predictive Value of Tests , Preoperative Care , Purines , Pyrazoles
4.
Clin Nephrol ; 77(3): 246-53, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22377258

ABSTRACT

Antibody-mediated rejection (AMR) following renal transplantation is less responsive to conventional anti-rejection therapies. Plasmapheresis (PP), intravenous immunoglobulin (IVIg), rabbit antithymocyte globulin (rATG) and rituximab deplete immature B-cells but not mature plasma cells. The proteasome inhibitor bortezomib has activity against mature plasma cell, the source of damaging donor-specific antibody (DSA).We present the successful use of bortezomib in 2 patients who developed AMR following kidney transplantation. The first patient was a 54-year-old white female who received living-unrelated kidney transplantation from her husband. She developed severe AMR early after transplantation with rising DSA titers consistent with an anamnestic immune response by memory cells to the donor antigens. Renal function deteriorated despite treatment with pulse methylprednisolone (MP), PP and IVIg. After initiation of therapy with bortezomib, DSA titers became negative and serum creatinine returned to baseline with histological resolution of AMR. The second patient was a 19-year-old white male who received deceased donor kidney transplantation and developed AMR within 2 weeks, refractory to therapy with pulse MP, PP and IVIg with rising DSA. Bortezomib use resulted in disappearance of DSA and renal function improvement. Both patients tolerated the treatment well with stable renal function at last follow-up. The novel mechanisms of action and preliminary results with bortezomib are encouraging, but require larger studies and longer follow-up.


Subject(s)
Boronic Acids/therapeutic use , Graft Rejection/drug therapy , Isoantibodies/blood , Kidney Failure, Chronic/surgery , Kidney Transplantation/immunology , Protease Inhibitors/therapeutic use , Proteasome Inhibitors , Pyrazines/therapeutic use , Adult , Biopsy , Bortezomib , Female , Graft Rejection/enzymology , Graft Rejection/immunology , Graft Rejection/pathology , Humans , Male , Middle Aged , Proteasome Endopeptidase Complex/metabolism , Severity of Illness Index , Treatment Outcome
6.
Article in English | MEDLINE | ID: mdl-20528437

ABSTRACT

We previously described the use of alemtuzumab as a pretreatment agent in 207 living-donor renal transplants, a trial that represented the largest series to date of live-donor renal and liver transplant recipients undergoing alemtuzumab pretreatment, and confirmed the short-term safety, efficacy and cost-effectiveness of this approach. This paper examines the use of the immunosuppressive combination of alemtuzumab and tacrolimus monotherapy in 47 patients with right-lobe adult living-donor liver transplantation.

7.
Am J Surg Pathol ; 30(8): 986-93, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16861970

ABSTRACT

In an attempt to more completely define the histopathologic features of the portal vein hyperperfusion or small-for-size syndrome (PHP/SFSS), we strictly identified 5 PHP/SFSS cases among 39 (5/39; 13%) adult living donor liver transplants (ALDLT) completed between 11/01 and 09/03. Living donor segments consisting of 3 right lobes, 1 left lobe, and 1 left lateral segment, with a mean allograft-to-recipient weight ratio (GRWR) of 1.0 +/- 0.3 (range 0.6 to 1.4), were transplanted without complications, initially, into 6 relatively healthy 25 to 63-year-old recipients. However, all recipients developed otherwise unexplained jaundice, coagulopathy, and ascites within 5 days after transplantation. Examination of sequential posttransplant biopsies and 3 failed allografts with clinicopathologic correlation was used in an attempt to reconstruct the sequence of events. Early findings included: (1) portal hyperperfusion resulting in portal vein and periportal sinusoidal endothelial denudation and focal hemorrhage into the portal tract connective tissue, which dissected into the periportal hepatic parenchyma when severe; and (2) poor hepatic arterial flow and vasospasm, which in severe cases, led to functional dearterialization, ischemic cholangitis, and parenchymal infarcts. Late sequelae in grafts surviving the initial events included small portal vein branch thrombosis with occasional luminal obliteration or recanalization, nodular regenerative hyperplasia, and biliary strictures. These findings suggest that portal hyperperfusion, venous pathology, and the arterial buffer response importantly contribute to early and late clinical and histopathologic manifestations of the small-for-size syndrome.


Subject(s)
Liver Diseases/etiology , Liver Diseases/physiopathology , Liver Transplantation/adverse effects , Living Donors , Portal System/physiopathology , Postoperative Complications/physiopathology , Adult , Aged , Female , Hepatic Artery/physiopathology , Humans , Liver/blood supply , Liver Circulation/physiology , Liver Diseases/surgery , Liver Transplantation/pathology , Male , Middle Aged , Portal Vein/physiopathology , Tissue and Organ Harvesting
8.
Transplantation ; 82(12): 1621-4, 2006 Dec 27.
Article in English | MEDLINE | ID: mdl-17198247

ABSTRACT

BACKGROUND: Alemtuzumab (Campath-1H) induction with tacrolimus monotherapy has been shown to provide effective immunosuppression for kidney, liver, lung, and small bowel transplantation. This drug combination was evaluated in pancreas transplant recipients. METHODS: Sixty consecutive pancreas transplants (30 simultaneous pancreas-kidney, 20 pancreas after kidney, and 10 pancreas alone) were carried out under this protocol between July 2003 to January 2005. The mean follow-up was 22 months (range 17-33). RESULTS: One-year patient, pancreas, and kidney allograft survival were 95%, 93%, and 90%, respectively. With 22 months follow-up, patient, pancreas, and kidney survival were 94%, 89%, and 87%, respectively. The rejection rate was 30% (18/60), with four patients (7%) experiencing steroid-resistant rejection. Major infection occurred in three (5%) patients resulting in two (3.3%) deaths from disseminated histoplasmosis and a herpes virus infection. One patient with cryptococcal meningitis was successfully treated. Seven (11.7%) patients experienced cytomegalovirus infection, all of whom responded to treatment with ganciclovir. One (1.7%) case of polymorphic posttransplant lymphoproliferative disease was seen, which regressed with a temporary discontinuation of tacrolimus and high-dose ganciclovir. The mean serum creatinine of the 30 simultaneous pancreas-kidney transplants at one year posttransplant was 1.37+/-0.33 mg/ml. The preexisting creatinine in pancreas after kidney transplants was not adversely affected by this immunosuppressive protocol. CONCLUSION: A single dose of perioperative alemtuzumab followed by daily tacrolimus monotherapy provides effective immunosuppression for pancreas transplantation, but the optimal use of this drug combination is not yet clear.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antibodies, Neoplasm/therapeutic use , Graft Rejection/prevention & control , Immunosuppression Therapy , Immunosuppressive Agents/therapeutic use , Pancreas Transplantation , Tacrolimus/therapeutic use , Alemtuzumab , Antibodies, Monoclonal, Humanized , Drug Therapy, Combination , Graft Rejection/complications , Graft Rejection/mortality , Graft Survival , Humans , Pancreas Transplantation/mortality , Treatment Outcome
9.
Transplantation ; 82(12): 1649-52, 2006 Dec 27.
Article in English | MEDLINE | ID: mdl-17198253

ABSTRACT

BACKGROUND: Alemtuzumab induction and tacrolimus-based immunosuppression has been effective in pancreas transplantation. Despite the encouraging results of this minimalistic approach to immunosuppression, infection still remains a significant cause of morbidity. The Cylex ImmuKnow [corrected] assay was used in this study to compare pancreas recipient clinical states (stable, rejection, infection) with T cell responses. METHODS: Blood samples were taken from pancreas recipients pretransplant and at approximately three-month intervals posttransplant for analysis of T cell responses. When possible, T cell responses were also quantified during changes in clinical status (infection or rejection). RESULTS: A range between 100-300 ng/ml adenosine triphosphate (ATP) was found in stable patients (mean 194+/-123, n = 51) with good graft function and no infection or rejection. A low T cell response was highly correlated with infectious states. The fourteen patients with infections/posttransplant lymphoproliferative disease had a mean ATP of 48 ng/ml. Risk hazard analysis showed that patients with ATP levels <100 ng/ml were four to seven times more susceptible to infection compared to stable patients. Four patients with rejection showed a T cell response of 550 ng/ml ATP, which was statistically significant compared to stable patients, although the sampling numbers (9) were too small to be conclusive. CONCLUSION: The Cylex ImmuKnow [corrected] assay is a valuable tool to more precisely modulate immunosuppression in pancreas transplant patients. In particular, the assay is extremely useful in detecting overly immunosuppressed patients vulnerable to infections.


Subject(s)
Antibodies, Monoclonal/administration & dosage , Antibodies, Neoplasm/administration & dosage , Immunosuppressive Agents/administration & dosage , Monitoring, Immunologic/methods , Pancreas Transplantation/immunology , T-Lymphocytes/drug effects , Tacrolimus/administration & dosage , Adenosine Triphosphate/blood , Alemtuzumab , Antibodies, Monoclonal, Humanized , Biological Assay , Graft Rejection/diagnosis , Graft Rejection/immunology , Humans , Infections/diagnosis , Infections/immunology , T-Lymphocytes/immunology
12.
Liver Transpl ; 11(3): 267-80, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15719409

ABSTRACT

Although calcineurin inhibitors (CNIs) remain the mainstay of immunosuppression in liver transplantation (LTX), their long-term toxicity significantly contributes to morbidity and mortality. The elucidation of mechanisms of alloimmunity and leukocyte migration have provided novel targets for immunosuppression development. The toxicities of these agents differ from that of the CNI and act additively or synergistically. CNI avoidance protocols in LTX have not been achieved routinely; however, pilot trials have begun to delineate the limitations and promises of such approaches. CNI-sparing protocols appear to be much more promising in balancing the early need for minimizing rejection while tapering doses and minimizing long-term toxicity.


Subject(s)
Calcineurin Inhibitors , Immunosuppression Therapy/trends , Immunosuppressive Agents/therapeutic use , Liver Transplantation/immunology , Adrenal Cortex Hormones/therapeutic use , Alemtuzumab , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Antibodies, Neoplasm/therapeutic use , Antibody Formation , Antilymphocyte Serum/therapeutic use , Humans , Mycophenolic Acid/therapeutic use , Sirolimus/therapeutic use , T-Lymphocytes/immunology
13.
Liver Transpl ; 10(10 Suppl 2): S39-53, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15382219

ABSTRACT

1. Liver transplantation for human immunodeficiency virus (HIV)-positive patients with end-stage liver disease in the era of highly active retroviral therapy has proven to be an effective treatment. The concerns of HIV progression have not been borne out by the growing worldwide experience. 2. CD4 counts are stable and HIV viral load is controllable with medication following liver transplantation. 3. Hepatitis C virus (HCV) coinfection in HIV-positive recipients is universal, but the severity of recurrence does not appear to be different from that in HIV-negative patients with HCV liver disease. 4. Complex pharmacokinetic interactions between the calcineurin inhibitors used for immunosuppression along with protease inhibitors are present, but management directed at recognizing the need for monitoring levels does not appear to increase the risk of toxicity. 5. The degree of immunosuppression from iatrogenic drug therapy and HIV does not lead to increased risk of infectious complications.


Subject(s)
HIV Infections/complications , Liver Failure/complications , Liver Failure/surgery , Liver Transplantation , AIDS-Related Opportunistic Infections/prevention & control , Antiretroviral Therapy, Highly Active , Drug Interactions , Graft Rejection , HIV Infections/drug therapy , Humans , Immunosuppressive Agents/therapeutic use , Liver Transplantation/standards , Liver Transplantation/trends
14.
Clin Transpl ; : 205-14, 2004.
Article in English | MEDLINE | ID: mdl-16704151

ABSTRACT

Campath-1H preconditioning with tacrolimus monotherapy is an effective immunosuppressive regimen for pancreas transplantation, with acceptable patient and graft survival rates early after transplantation. Rejection rates are low under this protocol if the tacrolimus level is kept consistently >10 ng/ml. This immunosuppressive protocol, combined with recent technical refinements, has resulted in lower rates of thrombosis and overall complications. Pancreatic transplantation en-bloc with visceral grafts has the following unique features: Diabetes is a rare indication, and HLA matching is not required. The gland is immunologically protected by the simultaneously transplanted visceral organs. Disease gravity, surgical complexity and gut alloimmunity influence the overall pancreatic allograft survival. The current UNOS listing criteria and data registry should be modified for obvious logistic and scientific reasons.


Subject(s)
Pancreas Transplantation/methods , Adolescent , Adult , Alemtuzumab , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Antibodies, Neoplasm/therapeutic use , Child , Diabetes Mellitus, Type 1/surgery , Graft Rejection , Graft Survival , Humans , Immunosuppressive Agents/therapeutic use , Middle Aged , Pancreas/anatomy & histology , Pancreas/surgery , Pancreas Transplantation/adverse effects , Pancreas Transplantation/immunology , Pancreas Transplantation/mortality , Pennsylvania/epidemiology , Survival Rate , Tacrolimus/therapeutic use , Tissue Donors , Transplantation Conditioning
SELECTION OF CITATIONS
SEARCH DETAIL
...